- Fervenza F C, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment[J]. Clinical Journal of the American Society of Nephrology, 2008, 3(3): 905-919.
- Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy[J]. Journal of the American Society of Nephrology, 2010, 21(4): 697-704.
- Honkanen E, Törnroth T, Grönhagen-Riska C, et al. Long-term survival in idiopathic membranous glomerulonephritis: can the course be clinically predicted?[J]. Clinical nephrology, 1994, 41(3): 127-134.
- Cattran D. Management of membranous nephropathy: when and what for treatment[J]. Journal of the American Society of Nephrology, 2005, 16(5): 1188-1194.
- Soleymanian T, Hamid G, Arefi M, et al. Non-diabetic renal disease with or without diabetic nephropathy in type 2 diabetes: clinical predictors and outcome[J]. Renal failure, 2015, 37(4): 572-575.
6.Soni S S, Gowrishankar S, Kishan A G, et al. Non diabetic renal disease in type 2 diabetes mellitus[J]. Nephrology, 2006, 11(6): 533-537.
7.Byun J M, Lee C H, Lee S R, et al. Renal outcomes and clinical course of nondiabetic renal diseases in patients with type 2 diabetes[J]. The Korean journal of internal medicine, 2013, 28(5): 565.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl, 2012, 2(2): 139-274.
9.van den Brand J A J G, van Dijk P R, Hofstra J M, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy[J]. Clinical Journal of the American Society of Nephrology, 2014, 9(6): 1066-1073.
10.Bhadauria D, Chellappan A, Kaul A, et al. Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary![J]. Clinical kidney journal, 2017, 11(1): 46-50.
- Chen M, Wang H Y, Li H, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial[J]. The American journal of the medical sciences, 2010, 339(3): 233-238.
12.Miller G, Zimmerman III R, Radhakrishnan J, et al. Use of mycophenolate mofetil in resistant membranous nephropathy[J]. American journal of kidney diseases, 2000, 36(2): 250-256.
- Bao H, Liu Z H, Xie H L, et al. Successful treatment of class V+ IV lupus nephritis with multitarget therapy[J]. Journal of the American Society of Nephrology, 2008, 19(10): 2001-2010.
14.Scott L . Tacrolimus : a further update of its use in the management of organ[J]. Drugs, 2003, 63.
15.Allison A C, Eugui E M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)[J]. Clinical transplantation, 1996, 10(1 Pt 2): 77-84.
16.Praga M, Barrio V, Juárez G F, et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial[J]. Kidney international, 2007, 71(9): 924-930.
17.Petrauskiene V, Falk M, Waernbaum I, et al. The risk of venous thromboembolism is markedly elevated in patients with diabetes[J]. Diabetologia, 2005, 48(5): 1017-1021.
18.Navar-Boggan A M, Peterson E D, D’Agostino Sr R B, et al. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease[J]. Circulation, 2015, 131(5): 451-458.
19.Hofstra J M, Branten A J W, Wirtz J J J M, et al. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial[J]. Nephrology Dialysis Transplantation, 2009, 25(1): 129-136.
20.Donadio Jr J V, Torres V E, Velosa J A, et al. Idiopathic membranous nephropathy: the natural history of untreated patients[J]. Kidney international, 1988, 33(3): 708-715.
21.Troyanov S, Wall C A, Scholey J W, et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission[J]. Kidney international, 2004, 66(3): 1199-1205.
22.Ramachandran R, Kumar V, Nada R, et al. Tacrolimus combined with corticosteroids versus M odified P onticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial[J]. Nephrology, 2016, 21(2): 139-146.
23.Randhawa P S, Shapiro R, Jordan M L, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine[J]. The American journal of surgical pathology, 1993, 17(1): 60.
24.Naesens M, Kuypers D R J, Sarwal M. Calcineurin inhibitor nephrotoxicity[J]. Clinical Journal of the American Society of Nephrology, 2009, 4(2): 481-508.
25.Spencer C M, Goa K L, Gillis J C. Tacrolimus[J]. Drugs, 1997, 54(6): 925-975.
26.Nankivell B J, Borrows R J, Fung C L S, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology[J]. Transplantation, 2004, 78(4): 557-565.
27.Wissmann C, Frey F J, Ferrari P, et al. Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: the role of the transplanted kidney[J]. Journal of the American Society of Nephrology, 1996, 7(12): 2677-2681.
28.Trence D L. Management of patients on chronic glucocorticoid therapy: an endocrine perspective[J]. Primary Care: Clinics in Office Practice, 2003, 30(3): 593-605.
29.Tamez-Pérez H E, Quintanilla-Flores D L, Rodríguez-Gutiérrez R, et al. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review[J]. World journal of diabetes, 2015, 6(8): 1073.
30.Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes[J]. Diabetes & metabolism, 2006, 32(5): 539-546.
31.Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus[J]. American Journal of Transplantation, 2007, 7(6): 1506-1514.
32.Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J]. New England journal of medicine, 1993, 329(14): 977-986.
33.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)[J]. The lancet, 1998, 352(9131): 837-853.